Patents by Inventor David G. Schatz

David G. Schatz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5851796
    Abstract: A tetracycline-regulated system which provides autoregulatory, inducible gene expression in cultured cells and transgenic animals is described. In the autoregulatory plasmid pTet-tTAk, a modified tTA gene called tTAk was placed under the control of Tetp. Tetracycline prevents tTA from binding to Tetp, preventing expression of both tTA and luciferase. This negative feedback cycle ensures that little or no tTA is produced in the presence of tetracycline, thereby reducing or eliminating possible toxic effects. When tetracycline is removed, however, this strategy predicts that tiny amounts of tTA protein (which may result from the leakiness of the minimal promoter), will bind to Tet-op and stimulate expression of the tTAk gene. A positive feedforward loop is initiated which in turn leads to higher levels of expression of tTA and thus, luciferase.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 22, 1998
    Assignee: Yale University
    Inventor: David G. Schatz
  • Patent number: 5159066
    Abstract: Recombination activating gene of mammalian origin (RAG-1), cDNA of RAG-1 of mammalian origin, mRNA expressed by RAG-1, the encoded recombinase and antibodies specific for the recombinase, as well as the use of the same for a diagnostic or therapeutic purpose.
    Type: Grant
    Filed: June 19, 1989
    Date of Patent: October 27, 1992
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: David G. Schatz, Marjorie A. Oettinger, David Baltimore